Medha N. Munshi, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypoglycemia | 20 | 2024 | 895 | 5.410 |
Why?
|
Diabetes Mellitus, Type 1 | 14 | 2024 | 3447 | 2.760 |
Why?
|
Blood Glucose Self-Monitoring | 15 | 2024 | 475 | 2.520 |
Why?
|
Blood Glucose | 29 | 2024 | 6430 | 2.510 |
Why?
|
Diabetes Mellitus, Type 2 | 40 | 2024 | 12252 | 2.510 |
Why?
|
Hypoglycemic Agents | 29 | 2024 | 3109 | 2.280 |
Why?
|
Diabetes Mellitus | 17 | 2024 | 5889 | 2.260 |
Why?
|
Insulin Infusion Systems | 4 | 2024 | 221 | 1.330 |
Why?
|
Insulin | 12 | 2024 | 6607 | 1.210 |
Why?
|
Aging | 9 | 2022 | 8744 | 1.040 |
Why?
|
Diabetes Complications | 6 | 2022 | 1320 | 0.950 |
Why?
|
Long-Term Care | 3 | 2020 | 631 | 0.840 |
Why?
|
Self Care | 6 | 2023 | 799 | 0.830 |
Why?
|
Hyperglycemia | 5 | 2017 | 1388 | 0.670 |
Why?
|
Metformin | 2 | 2024 | 909 | 0.670 |
Why?
|
Health Services for the Aged | 2 | 2018 | 264 | 0.640 |
Why?
|
Aged | 52 | 2024 | 171504 | 0.620 |
Why?
|
Frail Elderly | 4 | 2022 | 781 | 0.620 |
Why?
|
Aged, 80 and over | 29 | 2024 | 59629 | 0.600 |
Why?
|
Postprandial Period | 1 | 2019 | 320 | 0.570 |
Why?
|
Social Isolation | 1 | 2020 | 366 | 0.570 |
Why?
|
Walking | 1 | 2024 | 1201 | 0.570 |
Why?
|
Injections | 1 | 2019 | 840 | 0.510 |
Why?
|
Skilled Nursing Facilities | 2 | 2020 | 405 | 0.500 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 500 | 0.460 |
Why?
|
Telemedicine | 2 | 2023 | 3109 | 0.450 |
Why?
|
Pandemics | 4 | 2023 | 8748 | 0.450 |
Why?
|
Health Literacy | 1 | 2019 | 466 | 0.450 |
Why?
|
Patient-Centered Care | 2 | 2020 | 1444 | 0.430 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3115 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3238 | 0.400 |
Why?
|
Disease Management | 4 | 2018 | 2536 | 0.370 |
Why?
|
Technology | 2 | 2024 | 296 | 0.350 |
Why?
|
Humans | 74 | 2024 | 768166 | 0.350 |
Why?
|
Sulfonylurea Compounds | 4 | 2023 | 220 | 0.340 |
Why?
|
Nursing Homes | 6 | 2024 | 1084 | 0.330 |
Why?
|
Medication Adherence | 2 | 2019 | 2187 | 0.320 |
Why?
|
Health Facilities | 1 | 2014 | 578 | 0.320 |
Why?
|
Adaptation, Physiological | 1 | 2015 | 1312 | 0.310 |
Why?
|
Medicare | 5 | 2024 | 6809 | 0.310 |
Why?
|
C-Peptide | 2 | 2015 | 443 | 0.310 |
Why?
|
Patient Compliance | 2 | 2015 | 2697 | 0.300 |
Why?
|
Hypolipidemic Agents | 1 | 2012 | 609 | 0.290 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7454 | 0.290 |
Why?
|
Drug Delivery Systems | 1 | 2019 | 2232 | 0.290 |
Why?
|
Weight Gain | 1 | 2017 | 2359 | 0.280 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 2 | 2021 | 317 | 0.280 |
Why?
|
Comorbidity | 5 | 2023 | 10590 | 0.240 |
Why?
|
Dyslipidemias | 1 | 2012 | 873 | 0.240 |
Why?
|
Quality of Life | 8 | 2023 | 13490 | 0.230 |
Why?
|
Emergency Service, Hospital | 1 | 2024 | 7951 | 0.230 |
Why?
|
Disposable Equipment | 1 | 2024 | 46 | 0.230 |
Why?
|
Benchmarking | 2 | 2022 | 1057 | 0.230 |
Why?
|
Executive Function | 1 | 2012 | 1401 | 0.220 |
Why?
|
Life Style | 5 | 2024 | 3932 | 0.220 |
Why?
|
Middle Aged | 21 | 2024 | 223492 | 0.210 |
Why?
|
Cognition Disorders | 2 | 2008 | 3980 | 0.210 |
Why?
|
Polypharmacy | 2 | 2019 | 307 | 0.200 |
Why?
|
Physical Endurance | 1 | 2024 | 369 | 0.200 |
Why?
|
Geriatric Assessment | 2 | 2020 | 1422 | 0.190 |
Why?
|
Age Factors | 4 | 2020 | 18412 | 0.190 |
Why?
|
Cognition | 5 | 2023 | 7073 | 0.170 |
Why?
|
Male | 30 | 2024 | 364719 | 0.170 |
Why?
|
Caregivers | 2 | 2023 | 2302 | 0.160 |
Why?
|
Professional Role | 2 | 2015 | 316 | 0.160 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4860 | 0.160 |
Why?
|
Female | 32 | 2024 | 397192 | 0.160 |
Why?
|
Medicare Part D | 1 | 2023 | 355 | 0.150 |
Why?
|
Prevalence | 4 | 2017 | 15869 | 0.150 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 1667 | 0.140 |
Why?
|
Administration, Oral | 3 | 2017 | 4030 | 0.140 |
Why?
|
Drug Combinations | 1 | 2023 | 2089 | 0.140 |
Why?
|
New England | 1 | 2020 | 1058 | 0.140 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15662 | 0.140 |
Why?
|
Retrospective Studies | 10 | 2024 | 81762 | 0.140 |
Why?
|
Syndrome | 1 | 2023 | 3272 | 0.130 |
Why?
|
Elder Nutritional Physiological Phenomena | 1 | 2015 | 7 | 0.130 |
Why?
|
Homocysteine | 2 | 1997 | 637 | 0.130 |
Why?
|
Patient Education as Topic | 3 | 2015 | 2337 | 0.130 |
Why?
|
Glucose | 3 | 2023 | 4352 | 0.130 |
Why?
|
Voluntary Health Agencies | 1 | 1995 | 38 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2018 | 10760 | 0.120 |
Why?
|
Depressive Disorder | 1 | 2008 | 3721 | 0.120 |
Why?
|
Health Status Indicators | 1 | 2020 | 969 | 0.120 |
Why?
|
Adult | 12 | 2024 | 223646 | 0.120 |
Why?
|
Vulnerable Populations | 1 | 2020 | 718 | 0.120 |
Why?
|
Resilience, Psychological | 1 | 2022 | 807 | 0.120 |
Why?
|
Methionine | 2 | 1997 | 573 | 0.110 |
Why?
|
Risk | 2 | 2017 | 9613 | 0.110 |
Why?
|
Diabetic Angiopathies | 2 | 1997 | 806 | 0.110 |
Why?
|
Exercise | 4 | 2024 | 5955 | 0.110 |
Why?
|
Didanosine | 1 | 1994 | 151 | 0.110 |
Why?
|
Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 1994 | 30 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.110 |
Why?
|
Monitoring, Ambulatory | 1 | 2017 | 358 | 0.110 |
Why?
|
Needs Assessment | 1 | 2019 | 1141 | 0.110 |
Why?
|
Insulin, Long-Acting | 1 | 2013 | 59 | 0.100 |
Why?
|
United States | 9 | 2024 | 73039 | 0.100 |
Why?
|
Prospective Studies | 5 | 2019 | 54926 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2018 | 905 | 0.100 |
Why?
|
Trail Making Test | 1 | 2012 | 57 | 0.100 |
Why?
|
Pregnancy in Diabetics | 1 | 1994 | 198 | 0.100 |
Why?
|
Hypertension | 2 | 2012 | 8616 | 0.100 |
Why?
|
Obesity, Morbid | 1 | 2023 | 1298 | 0.100 |
Why?
|
Peptides | 1 | 2023 | 4354 | 0.100 |
Why?
|
Cohort Studies | 4 | 2021 | 41754 | 0.090 |
Why?
|
Delivery of Health Care | 1 | 2009 | 5367 | 0.090 |
Why?
|
Medical Staff, Hospital | 1 | 1995 | 603 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26379 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2017 | 964 | 0.090 |
Why?
|
Myocardial Infarction | 2 | 2022 | 11519 | 0.090 |
Why?
|
Data Interpretation, Statistical | 1 | 2020 | 2709 | 0.090 |
Why?
|
Weight Loss | 4 | 2023 | 2721 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2024 | 2298 | 0.080 |
Why?
|
Vasodilation | 1 | 2013 | 967 | 0.080 |
Why?
|
Psychotherapy, Group | 1 | 2013 | 417 | 0.080 |
Why?
|
Body Mass Index | 2 | 2024 | 13053 | 0.080 |
Why?
|
Endocrinology | 1 | 1995 | 443 | 0.080 |
Why?
|
Physician's Role | 1 | 2015 | 925 | 0.080 |
Why?
|
Statistics as Topic | 1 | 2015 | 2357 | 0.080 |
Why?
|
HIV Seropositivity | 1 | 1994 | 966 | 0.080 |
Why?
|
Dementia | 1 | 2023 | 2740 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2017 | 39348 | 0.080 |
Why?
|
Young Adult | 3 | 2019 | 60066 | 0.070 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 687 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2873 | 0.070 |
Why?
|
Depression | 2 | 2020 | 8230 | 0.070 |
Why?
|
Treatment Outcome | 7 | 2024 | 65371 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6316 | 0.070 |
Why?
|
Sodium | 2 | 2023 | 1597 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10399 | 0.070 |
Why?
|
Cost of Illness | 1 | 2015 | 1951 | 0.060 |
Why?
|
Motor Activity | 1 | 2015 | 2711 | 0.060 |
Why?
|
Pharmacists | 1 | 2008 | 261 | 0.060 |
Why?
|
Cell Adhesion Molecules | 1 | 2011 | 1613 | 0.060 |
Why?
|
Cerebrovascular Circulation | 2 | 2013 | 2725 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4055 | 0.060 |
Why?
|
Posture | 1 | 2009 | 957 | 0.060 |
Why?
|
Risk Factors | 5 | 2020 | 74944 | 0.060 |
Why?
|
Hospitalization | 1 | 2024 | 10840 | 0.060 |
Why?
|
Postural Balance | 1 | 2009 | 639 | 0.060 |
Why?
|
Boston | 1 | 2017 | 9374 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8542 | 0.060 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2009 | 952 | 0.050 |
Why?
|
Glipizide | 1 | 2022 | 48 | 0.050 |
Why?
|
Regression Analysis | 1 | 2012 | 6340 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5520 | 0.050 |
Why?
|
Incidence | 2 | 2018 | 21538 | 0.050 |
Why?
|
Glyburide | 1 | 2022 | 117 | 0.050 |
Why?
|
Pregnancy Complications, Infectious | 1 | 1994 | 2185 | 0.050 |
Why?
|
Obesity | 2 | 2023 | 13090 | 0.050 |
Why?
|
Health Behavior | 1 | 2013 | 2650 | 0.050 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2021 | 88 | 0.050 |
Why?
|
Overweight | 2 | 2023 | 2448 | 0.050 |
Why?
|
Stroke | 1 | 2022 | 9755 | 0.040 |
Why?
|
Brain | 3 | 2013 | 27360 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2014 | 7852 | 0.040 |
Why?
|
Hand Strength | 1 | 2022 | 466 | 0.040 |
Why?
|
Homes for the Aged | 1 | 2021 | 273 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15454 | 0.040 |
Why?
|
Disabled Persons | 1 | 2008 | 1210 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9495 | 0.040 |
Why?
|
Risk Assessment | 1 | 2019 | 24315 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2021 | 374 | 0.040 |
Why?
|
Caloric Restriction | 1 | 2020 | 301 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2012 | 4310 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2020 | 487 | 0.030 |
Why?
|
Internship and Residency | 1 | 1995 | 5953 | 0.030 |
Why?
|
Chicago | 1 | 1995 | 255 | 0.030 |
Why?
|
Entropy | 1 | 2014 | 211 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1969 | 0.030 |
Why?
|
Hospitals, University | 1 | 1995 | 570 | 0.030 |
Why?
|
Osteoblasts | 1 | 1998 | 1145 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2021 | 2430 | 0.020 |
Why?
|
Zidovudine | 1 | 1994 | 625 | 0.020 |
Why?
|
Fasting | 1 | 2018 | 1610 | 0.020 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1942 | 0.020 |
Why?
|
Administration, Intranasal | 1 | 2013 | 485 | 0.020 |
Why?
|
Medical History Taking | 1 | 1995 | 779 | 0.020 |
Why?
|
Estrogens | 1 | 1998 | 1536 | 0.020 |
Why?
|
Osteogenesis | 1 | 1998 | 1288 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 1998 | 2414 | 0.020 |
Why?
|
Adolescent | 1 | 2019 | 89169 | 0.020 |
Why?
|
Demography | 1 | 1995 | 1641 | 0.020 |
Why?
|
Physical Examination | 1 | 1995 | 1263 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1703 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2015 | 22291 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3212 | 0.020 |
Why?
|
HIV Infections | 1 | 1994 | 17569 | 0.020 |
Why?
|
Diabetic Retinopathy | 1 | 1996 | 1300 | 0.020 |
Why?
|
Magnetic Resonance Angiography | 1 | 2013 | 1429 | 0.020 |
Why?
|
Prediabetic State | 1 | 2012 | 548 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12543 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 1994 | 1798 | 0.020 |
Why?
|
Atrophy | 1 | 2011 | 1646 | 0.020 |
Why?
|
Oxidative Stress | 1 | 1997 | 3139 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3706 | 0.020 |
Why?
|
Chronic Disease | 1 | 2020 | 9384 | 0.020 |
Why?
|
Stem Cells | 1 | 1998 | 3537 | 0.020 |
Why?
|
Feedback | 1 | 2009 | 799 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 1995 | 2176 | 0.010 |
Why?
|
Memory | 1 | 2013 | 2208 | 0.010 |
Why?
|
Time Factors | 2 | 1996 | 40218 | 0.010 |
Why?
|
Smoking Cessation | 1 | 1995 | 2085 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 7140 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3858 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2013 | 12465 | 0.010 |
Why?
|
Thiobarbiturates | 1 | 1997 | 4 | 0.010 |
Why?
|
Osteocalcin | 1 | 1998 | 275 | 0.010 |
Why?
|
Free Radicals | 1 | 1997 | 238 | 0.010 |
Why?
|
Alendronate | 1 | 1998 | 174 | 0.010 |
Why?
|
Lipid Peroxidation | 1 | 1997 | 276 | 0.010 |
Why?
|
Ovariectomy | 1 | 1998 | 613 | 0.010 |
Why?
|
Basement Membrane | 1 | 1996 | 348 | 0.010 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1998 | 399 | 0.010 |
Why?
|
Peripheral Vascular Diseases | 1 | 1997 | 488 | 0.010 |
Why?
|
Bone Resorption | 1 | 1998 | 728 | 0.010 |
Why?
|
Family Practice | 1 | 1996 | 509 | 0.010 |
Why?
|
Proteinuria | 1 | 1996 | 611 | 0.010 |
Why?
|
Pregnancy | 2 | 1994 | 30256 | 0.010 |
Why?
|
Pregnanes | 1 | 1971 | 7 | 0.010 |
Why?
|
Amino Acids | 1 | 1998 | 1716 | 0.010 |
Why?
|
Carotid Artery Diseases | 1 | 1997 | 879 | 0.010 |
Why?
|
Retinal Vessels | 1 | 1996 | 864 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1997 | 6229 | 0.000 |
Why?
|
Blood | 1 | 1971 | 599 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1996 | 4427 | 0.000 |
Why?
|
Brain Ischemia | 1 | 1997 | 3007 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 36743 | 0.000 |
Why?
|
Referral and Consultation | 1 | 1996 | 3620 | 0.000 |
Why?
|
Cost-Benefit Analysis | 1 | 1996 | 5536 | 0.000 |
Why?
|
Coronary Disease | 1 | 1997 | 5919 | 0.000 |
Why?
|
Cell Differentiation | 1 | 1998 | 11669 | 0.000 |
Why?
|
Smoking | 1 | 1996 | 9092 | 0.000 |
Why?
|
Disease Progression | 1 | 1996 | 13671 | 0.000 |
Why?
|
Buffaloes | 1 | 1971 | 14 | 0.000 |
Why?
|
Estrus | 1 | 1971 | 70 | 0.000 |
Why?
|
Mice | 1 | 1998 | 82029 | 0.000 |
Why?
|
Blood Chemical Analysis | 1 | 1971 | 435 | 0.000 |
Why?
|
Animals | 2 | 1998 | 169246 | 0.000 |
Why?
|
Blood Coagulation | 1 | 1971 | 1162 | 0.000 |
Why?
|